The approval of the new cetuximab (Erbitux) dosage – 500 mg/m2 as a two-hour IV infusion every two weeks – was based on population pharmacokinetic (PK) modeling analyses and provides an alternative option to the previously approved weekly dose. Cetuximab can be dosed alone or in combination with chemotherapy.
According to the results of a new clinical trial published in The New England Journal of Medicine (NEJM), a simple treatment that combines four heart medicines in one pill—a “polypill”—was able to cut the risk of heart attack, stroke, and other cardiovascular events by 21% in people at risk of heart disease, and by 31% […]
The possible answer was presented during the 2020 ASH Annual Meeting, bringing into question whether current recommendations for prophylactic intravenous high-dose methotrexate — the most widely adopted method for CNS relapse prevention — are appropriate for all patients at high risk of a CNS relapse.
According to an international task force at the virtual PAINWeek meeting, chronic pain patients can be treated with medical cannabis following one of three protocols based on patient characteristics. The recommendations are timely considering the limited clinician knowledge about medical cannabis treatment and the opioid crisis.
In this podcast from the virtual 2020 ESMO World Congress on Gastrointestinal Cancer, Dr. Zev Wainberg discusses emerging data from the phase 1/2 trial of first-line liposomal irinotecan plus 5-fluorouracil/leucovorin plus oxaliplatin for pancreatic ductal adenocarcinoma (PDAC).
According to the results of a single-arm, multicenter phase 2 trial in JAMA Oncology, low-dose erlotinib may be a safe and effective option for frail or elderly patients with EGFR mutation-positive NSCLC.